July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Raul Cordoba: Nivolumab-AVD vs Brentuximab Vedotin–AVD in Advanced-Stage Classic Hodgkin Lymphoma
Jun 18, 2025, 09:15

Raul Cordoba: Nivolumab-AVD vs Brentuximab Vedotin–AVD in Advanced-Stage Classic Hodgkin Lymphoma

Raul Cordoba, Chair of Community Stakeholder Committee at European Hematology Association (EHA), shared a post on X:

“Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826 |⁩ Journal of Clinical Oncology”

Title: Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826

Authors: Sarah C. Rutherford, Hongli Li, Alex F. Herrera, Michael LeBlanc, Sairah Ahmed, Kelly Davison, Susan K. Parsons, Joseph M. Unger, Anamarija M. Perry, Carla Casulo, Nancy L. Bartlett, Joseph M. Tuscano, Brian T. Hess, Pallawi Torka, Pankaj Kumar, Ryan Jacobs, Joo Y. Song, Sharon M. Castellino, Brad Kahl, John P. Leonard, Sonali M. Smith, Jonathan W. Friedberg, Andrew M. Evens

Read Full Article.

Nivolumab-AVD Nivolumab-AVD

More posts featuring Raul Cordoba on OncoDaily